Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (515)	11/4/2005 11:34:07 AM
From: keokalani'nui	Read Replies (2) of 590

Miljenko, From what mopgcw (thanks!) just posted. Sorry I was a little off (by either 1/3 or 1/4!). Still, same non-conculsion drawn. However, the high (75%) progression rate by 8 weeks makes the clinical benefit somewhat difficult to interpret. It is also not appropriate to compare the data against those on Erbitux.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next